journal article·2022-08

Autophagy inhibition recovers deficient ICD-based cancer immunotherapy

Jinbo Li, Wenxu Cai, Jiang Yu, Shuang Zhou, Xianlu Li, Zhonggui He, Defang Ouyang, Hongzhuo Liu, Yongjun Wang

Biomaterials· Volume 287
Publisher page

Abstract

ICD effect is usually accompanied with robust autophagy that can depredate immune-associated antigens in tumors, thereby weakening the immune response against tumor growth. To circumvent this dilemma, we combined an ICD inducer (Shikonin, SHK) with an autophagy inhibitor (hydroxychloroquine, HCQ) for colon cancer immunotherapy. Notably, HCQ boosted SHK-induced antigen exposure in colon cancer in vitro and in vivo. However, autophagy inhibition caused loss of ATP, which compromised antitumor immune response. Therefore, a compensatory strategy was employed by introducing ATP as a remote loading gradient of the liposome to encapsulate HCQ (LipHCQa). LipHCQa achieved an excellent antitumor efficiency without dampening the immune response. Furthermore, a systematic determination of the optimal dosage of combined LipSHK and LipHCQa suggested that autophagy inhibiting at an appropriate dosage level was beneficial for maximizing ICD-based antitumor immunity. This study proved that autophagy inhibitors can recover the deficient ICD-based antitumor immune response and present potential clinical applications for cancer immunotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Adenosine and Purinergic Signaling · Phagocytosis and Immune Regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (34)

Show source-provided references
1. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis10.1016/S1470-2045(21)00333-8 ↗
2. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
3. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
4. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death10.1084/jem.20050915 ↗
5. Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy10.1016/j.jconrel.2021.05.040 ↗
6. Autophagy balances inflammation in innate immunity10.1080/15548627.2017.1402992 ↗
7. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors10.1038/nm.2028 ↗
8. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice
9. Molecular mechanisms of ATP secretion during immunogenic cell death10.1038/cdd.2013.75 ↗
10. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma10.1021/acsnano.0c00708 ↗
11. Autophagy regulates stress responses, metabolism, and anticancer immunity10.1016/j.trecan.2021.05.003 ↗
12. Autophagy in tumour immunity and therapy10.1038/s41568-021-00344-2 ↗
13. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I10.1038/s41586-020-2229-5 ↗
14. Recent progress of autophagy signaling in tumor microenvironment and its targeting for possible cancer therapeutics
15. Combinatorial strategies for the induction of immunogenic cell death
16. Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance10.1080/15548627.2017.1386359 ↗
17. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-110.1002/advs.202002147 ↗
18. Molecular and genetic properties of tumors associated with local immune cytolytic activity10.1016/j.cell.2014.12.033 ↗
19. Engineering Chameleon Prodrug nanovesicles to increase antigen presentation and inhibit PD-L1 expression for circumventing immune resistance of cancer10.1002/adma.202102668 ↗
20. Functions and implications of autophagy in colon cancer10.3390/cells8111349 ↗
21. Smart transformable nanomedicines for cancer therapy10.1016/j.biomaterials.2021.120737 ↗
22. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia10.1200/JCO.2012.44.5643 ↗
23. Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial10.1200/JCO.2012.44.4711 ↗
24. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma10.1186/s12943-020-01297-0 ↗
25. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma10.4161/auto.29118 ↗
26. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy10.1038/s41565-021-00950-z ↗
27. Endogenous HMGB1 regulates autophagy10.1083/jcb.200911078 ↗
28. Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies10.4161/auto.27901 ↗
29. Autophagy in human diseases10.1056/NEJMra2022774 ↗
30. Immunological consequences of chemotherapy: single drugs, combination therapies and nanoparticle-based treatments10.1016/j.jconrel.2019.04.020 ↗
31. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
32. Furin-instructed aggregated gold nanoparticles for re-educating tumor associated macrophages and overcoming breast cancer chemoresistance10.1016/j.biomaterials.2021.120891 ↗
33. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype10.1038/s41467-018-03225-9 ↗
34. Emerging role of autophagy in anti-tumor immunity: implications for the modulation of immunotherapy resistance10.1016/j.drup.2021.100752 ↗